Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7450943 | 0.94 | CYP2C19 (0.64) | CYP2C19HSD17B10SMN1; SMN2RAB9AMMP8 | |
| SCHEMBL9024631 | 0.89 | CYP2C19 (0.58) | CYP2C19HSD17B10SMN1; SMN2RAB9AMMP8 | |
| SCHEMBL28997199 | 0.86 | CYP2C19 (0.72) | CYP2C19RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4371675 | 0.86 | CYP2C19 (0.72) | CYP2C19SMN1; SMN2RAB9ASLC1A3SLC1A2 | |
| SCHEMBL1766985 | 0.83 | CYP2C19 (1.00) | CYP2C19SMN1; SMN2RAB9ASLC1A3SLC1A2 | |
| SCHEMBL4103378 | 0.83 | CYP2C19 (0.53) | CYP2C19HSD17B10SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20543720 | 0.81 | CTSC (0.55) | CYP2C19HSD17B10SMN1; SMN2RAB9ASLC1A3 | |
| SCHEMBL29278210 | 0.81 | CYP2C19 (0.51) | CYP2C19HSD17B10SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8332586 | 0.81 | SMN1; SMN2 (0.48) | CYP2C19HSD17B10SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11729865 | 0.81 | CYP2C19 (0.49) | CYP2C19HSD17B10SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-03-03 | — | — | US | claimed |
| EP-2257540-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-08 | — | — | EP | claimed |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2010-06-03 | — | — | US | claimed |
| WO-2009122421-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-08 | — | — | WO | claimed |
| EP-2097408-A1 | IMPROVED PROCESS FOR EPROSARTAN | Hetero Drugs Limited (IN) | 2009-09-09 | — | — | EP | claimed |
| WO-2009084028-A2 | IMPROVED PROCESS FOR MANUFACTURING ANHYDROUS (E)-3-[2-BUTYL-1- {(4-CARBOXYPHENYL) METHYL}-1H-IMIDAZOLE-5-YL]-(THIOPHEN-2- YLMETHYL)PROP-2-ENOIC ACID METHANE SULFONATE | NEULAND LABORATORIES LTD (IN) | 2009-07-09 | — | — | WO | claimed |
| WO-2008078330-A1 | IMPROVED PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2008-07-03 | — | — | WO | claimed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | claimed |
| US-8361507-B2 | Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan | HETERO DRUGS LIMITED (IN) | 2013-01-29 | — | — | US | disclosed |
| WO-2009122421-A3 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011051975-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PURE EPROSARTANAND ITS PHARMACEUTICAL ACCEPTABLE SALTS | MATRIX LABORATORIES LTD (IN) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011004384-A3 | PROCESS FOR THE PREPARATION OF EPROSARTAN | GLOCHEM INDUSTRIES LIMITED (IN) | 2011-04-21 | — | — | WO | disclosed |
| EP-2295431-A2 | Substantially pure eprosartan free base | Hetero Drugs Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295430-A2 | Crystalline solid of eprosartan acetate | Hetero Drugs Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| CN-1070645-A | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 1993-04-07 | — | — | CN | disclosed |
| WO-1993003722-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1992020651-A2 | N-(HETEROARYL)-IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992010189-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | PTGER1, PTGER4, PDGFRA | CYP2C19 616/4885HSD17B10 1655/4885SMN1; SMN2 2663/4885 |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | PTMA, PTGER1, PDGFRA | CYP2C19 231/4885HSD17B10 1515/4885SMN1; SMN2 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.